CDTX - a competitor to CYDY's CCR5 MOA? Abstra
Post# of 148111
(Total Views: 606)
Posted On: 03/28/2024 1:02:51 PM
CDTX - a competitor to CYDY's CCR5 MOA?
Abstract Title: CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
Presenter: Simon Döhrmann, Ph.D.
Session Category: Immunology
Session Title: Single Target and Bispecific Antibodies
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Poster Board Number: 22, Section 6
Abstract Title: CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
Presenter: Simon Döhrmann, Ph.D.
Session Category: Immunology
Session Title: Single Target and Bispecific Antibodies
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Poster Board Number: 22, Section 6
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼